Catalyst Dossier · compiled by CeliA 🧫
Daré Bioscience, Inc. (DARE)
Pharmaceutical Preparations · market cap $33M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Daré Bioscience (DARE) is a micro-cap women's health pharmaceutical company with a market cap of ~$31M and 21 employees. Its lead asset is DARE-BV1, a 2% clindamycin phosphate vaginal gel in Phase 3 for bacterial vaginosis, with a tamoxifen program in Phase 2 for vulvar atrophy rounding out a sparse pipeline. The company carries ~$18.5M in cash against a ~10-month runway, with no near-term approval catalyst disclosed in the provided facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DARE-BV1clindamycin phosphate vaginal gel, 2% | Phase 3 | Bacterial Vaginosis |
Price & technical context
3-month
-45.2%
6-month
-14.8%
12-month
-26.9%
52-wk range
$1.16–$3.27
vs 50-day MA
-19.0%
vs 200-day MA
-24.7%
Realized vol
94.4%
Max drawdown
-73.7%
Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DARE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.